Q1 2023 Earnings Forecast for Invivyd, Inc. Issued By Jefferies Financial Group (NASDAQ:IVVD)

Invivyd, Inc. (NASDAQ:IVVDGet Rating) – Equities researchers at Jefferies Financial Group issued their Q1 2023 earnings per share estimates for Invivyd in a report released on Friday, November 11th. Jefferies Financial Group analyst M. Yee anticipates that the company will earn ($0.42) per share for the quarter. The consensus estimate for Invivyd’s current full-year earnings is ($2.37) per share. Jefferies Financial Group also issued estimates for Invivyd’s Q2 2023 earnings at ($0.45) EPS, Q3 2023 earnings at ($0.43) EPS and Q4 2023 earnings at ($0.46) EPS.

Separately, Morgan Stanley assumed coverage on shares of Invivyd in a research note on Wednesday, September 14th. They issued an “underweight” rating and a $3.00 target price on the stock.

Invivyd Stock Performance

NASDAQ:IVVD opened at $3.60 on Monday. The company has a 50 day moving average price of $3.50. Invivyd has a 12 month low of $2.41 and a 12 month high of $78.82. The company has a market capitalization of $395.73 million, a price-to-earnings ratio of -1.39 and a beta of -0.39.

About Invivyd

(Get Rating)

Invivyd, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease.

Further Reading

Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.